A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis

Annals of the Rheumatic Diseases

Volumn 67, Issue 6, 2008, Pages 855-859

  Ravindran, V ^a   Scott, D L ^a   Choy, E H ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; AURANOFIN; AZATHIOPRINE; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PENICILLAMINE; PLACEBO; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TOXICITY; DRUG WITHDRAWAL; EMBASE; HUMAN; LOW DRUG DOSE; MEDLINE; META ANALYSIS; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; BIOLOGICAL PRODUCTS; HUMANS; ISOXAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT FUSION PROTEINS; RISK ASSESSMENT; SULFASALAZINE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 45149113887     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.072652     Document Type: Review

References (50)

1. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727- 35.
2. Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39:2013-20.
3. Begg C, Cho M, Eastwood S Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomised controlled trials. The CONSORT statement. J Am Med Assoc 1996;276:637-9.
4. Choy E H S, Smith C, Doré C J, Scott DL. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology 2005;44:1414-21.
5. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized controlled trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
6. Caperton EM, Heim-Duthoy KL, Matzke GR. Ceftriaxone therapy of chronic inflammatory arthritis: a double-blind placebo controlled trial. Arch Intern Med 1990;150:1677-82.
7. Fierlbeck G, Rassner G. Treatment of psoriasis and psoriatic arthritis with interferon gamma. J Invest Dermatol 1990;95:138- 41S.
8. Veale DJ, Torley HI, Richards IM, O'Dowd, A, Fitzsimons C, Belch JJ, et al. A double-blind placebo controlled trial of efamol marine on skin and joint symptoms of psoriatic arthritis. Br J Rheumatol 1994;33:954-8.
9. Dalbeth N, Yeoman S, Dockerty JL, Highton J, Robinson E, Tan PL, et al. A randomized placebo controlled trial of delipidated, deglycolipidated Mycobacterium vaccae as immunotherapy for psoriatic arthritis. Ann Rheum Dis 2004;63:718-22.
10. McKendry RJR, Kraag G, Seigel S, Al-Awadhi A. Therapeutic value of colchicine in the treatment of patients with psoriatic arthritis. Ann Rheum Dis 1993;52:826-8.
11. Seideman P, Fjellner B, Johanesson L. Psoriatic arthritis treated with oral colchicine. J Rheumatol 1987;14:777-9.
12. Sarzi-Puttini P, Santandrea S, Boccassini L, Panni B, Caruso I. The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin Exp Rheumatol 2001;19(S22):S17-20.
13. Black RL, O'Brien WM, Vanscott EJ, Auerbach R, Eisen AZ, Bunim JJ. Methotrexate in patients with psoriatic arthritis: double blind study on 21 patients. JAMA 1964;189:743-7.
14. Peeters AJ, Dijkmans BA, van der Schroeff JG. Fumaric acid therapy for Psoriatic arthritis. A randomized, double blind, placebo controlled study. Br J Rheumatol 1992;31:502-3.
15. Salvarani C, Macchioni P, Olivieri I, Marchesoni A, Cutolo M, Ferraccioli G, et al. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 2001;28:2274-82.
16. Spadaro A, Riccieri V, Sili-Scavalli A, Sensi F, Taccari E, Zoppini A. Comparison of cyclosporine A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol 1995;13:589-93.
17. Bruckle W, Dexel T, Grasedyck K, Schattenkirchner M. Treatment of psoriatic arthritis with auranofin and gold sodium thiomalate. Clin Rheumatol 1994;13:209-16.
18. Hopkins R, Bird HA, Jones H, Hill J, Surrall KE, Astbury C, et al. A double blind controlled trial of etretinate (Tigason) and ibuprofen in psoriatic arthritis. Ann Rheum Dis 1985;44:189-9.
19. Dougados M, van der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys E, et al. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double blind, placebo-controlled study. Arthritis Rheum 1995;38:618-27.
20. Fraser AD, van Kuijk AWR, Westhovens R, Karim Z, Wakefield R, Gerards AH, et al. A randomized, double blind, placebo controlled multicentre trial of combination therapy with methotrexate plus cyclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 2005;64:859-64.
21. Willkens RF, Williams HJ, Ward JR, Egger MJ, Reading JC, Clements PJ, et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984;27:376-81.
22. Fraser SM, Hopkins R, Hunter JA, Neumann V, Capell HA, Bird HA. Sulfasalazine in the management of psoriatic arthritis. Br J Rheumatol 1993;32:923-5.
23. Gupta AK, Grober JS, Hamilton TA, Ellis CN, Siegel MT, Voorhees JJ, et al. Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J Rheumatol 1995;22:894-8.
24. Farr M, Kitas GD, Waterhouse L, Jubb R, Felix-Davies D, Bacon PA. Sulfasalazine in psoriatic arthritis: a double-blind placebo-controlled study. Br J Rheumatol 1990;29:46-9.
25. Combe B, Goupille P, Kuntz JL, Tebib J, Liote F, Bregeon C. Sulfasalazine in psoriatic arthritis: a randomized, multicentre, placebo-controlled study. Br J Rheumatol 1996;35:664-8.
26. Carrette S, Calin A, McCafferty JP, Wallin BA. Evaluation of auranofin in psoriatic arthritis: a double blind placebo controlled trial. Arthritis Rheum 1989;32:158-65.
27. Palit J, Hill J, Capell HA, Carey J, Daunt SO, Cawley MI, et al. A multicentre double-blind comparison of auranofin, intramuscular gold thiomalate and placebo in patients with psoriatic arthritis. Br J Rheumatol 1990;29:280-3.
28. Levy JJ, Paulus HE, Barnett EV, Sokoloff M, Bangert R, Pearson CM. A double-blind controlled evaluation of azathioprine treatment in rheumatoid arthritis and psoriatic arthritis. Arthritis Rheum 1972;15:116-17.
29. Price R, Gibson T. d-Penicillamine and psoriatic arthropathy. Br J Rheumatol 1986;25:228.
30. Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis. Arthritis Rheum 2004;50:1939-50.
31. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90.
32. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72.
33. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al., Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89.
34. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum 2005;52:1227-36.
35. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150-7.
36. Mease PJ, Gladman DD, Keystone EC. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: result of a randomized, double blind, placebo-controlled study. Arthritis Rheum 2006;54:1638-45.
37. Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp JT, Ory PA, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 2007;56:476-88.
38. Papp KA, Caro I, Leung HM, Garovoy M, Mease PJ. Efalizumab for the treatment of psoriatic arthritis. J Cutan Med Surg 2007;11:57-66.
39. Mease PJ, Antoni CE, Gladman DD, Taylor WJ. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005;64:49-54.
40. Kavanaugh AF, Ritchlin CT; GRAPPA Treatment Guideline Committee. Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol 2006;33:1417-21.
41. Soriano ER, McHugh NJ. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol 2006;33:1422-30.
42. Nash P. Therapies for axial disease in psoriatic arthritis. A systematic review. J Rheumatol 2006;33:1431-4.
43. Ritchlin CT. Therapies for psoriatic enthesopathy. A systematic review. J Rheumatol 2006;33:1435-8.
44. Helliwell PS. Therapies for dactylitis in psoriatic arthritis. A systematic review. J Rheumatol 2006;33:1439-41.
45. Cassell S, Kavanaugh AF. Therapies for psoriatic nail disease. A systematic review. J Rheumatol 2006;33:1452-6.
46. Gladman DD. Traditional and newer therapeutic options for psoriatic arthritis: an evidence-based review. Drugs 2005;65:1223- 38.
47. Jones G, Crotty M, Brooks P. Psoriatic arthritis: a quantitative overview of therapeutic options. The Psoriatic Arthritis Meta-Analysis Study Group. Br J Rheumatol 1997;36:95-9.
48. Jones G, Brooks P, Crotty M. Interventions for treating psoriatic arthritis (Cochrane Review). In: The Cochrane Library, Issue 4, 2005: Oxford Update Software.
49. Woolacott NF, Khadjesari ZC, Bruce IN, Riemsma RP. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review. Clin Exp Rheumatol 2006;24:587-93.
50. Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, et al. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 2006;10:1-239.